CN1121807A - 癌灵注射液 - Google Patents

癌灵注射液 Download PDF

Info

Publication number
CN1121807A
CN1121807A CN95108768.1A CN95108768A CN1121807A CN 1121807 A CN1121807 A CN 1121807A CN 95108768 A CN95108768 A CN 95108768A CN 1121807 A CN1121807 A CN 1121807A
Authority
CN
China
Prior art keywords
injection
ailing
anticancer
leukemia
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN95108768.1A
Other languages
English (en)
Other versions
CN1044559C (zh
Inventor
张亭栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital Of Harbin Medical University
Original Assignee
First Affiliated Hospital Of Harbin Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5076886&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1121807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by First Affiliated Hospital Of Harbin Medical University filed Critical First Affiliated Hospital Of Harbin Medical University
Priority to CN95108768A priority Critical patent/CN1044559C/zh
Publication of CN1121807A publication Critical patent/CN1121807A/zh
Priority to US08/702,011 priority patent/US6720011B1/en
Application granted granted Critical
Publication of CN1044559C publication Critical patent/CN1044559C/zh
Priority to US10/715,166 priority patent/US20040101573A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种治疗白血病的癌灵注射液，主要由三氧化二砷、氯化钠、注射用水，经煮沸过滤灭菌制成癌灵注射液，其中三氧化二砷1-10克，氯化钠8克，注射用水1000毫升。用静脉滴注，对急性早幼粒细胞性白血病治疗缓解率高，长期存活率大，完全缓解率为84％，长期存活者已达21年之久。该注射液对白血病细胞膜的破坏、DNA、RNA合成抑制及克隆增殖能力的丧失具有较强的作用；对白血病细胞有显著的杀伤作用。

Description

癌灵注射液
本发明是属于治疗癌症的一种药品。
白血病是造血***的肿瘤，又称血癌，是当今危及人类生命的恶性疾病，一旦发病其自然生存期为3—6个月。其中尤其急性早幼粒细胞白血病，治疗难度大，死亡率高，长期存活十分困难。目前治疗主要是化疗为主，国外儿童急粒完全缓解率为75％，成人为70—80％，5年无病生存率为35—40％；骨髓移植4年生存率59％。国内急粒完全缓解率为60—70％，5年无病生存率不足10％；应用维甲酸治疗完全缓解率可达85％，为世界先进水平，但易复发，而且复发后再用此药治疗也不可能再次收到疗效，并且副作用强，病人常因此不能耐受而停药，使治疗失败。
本发明提出一种癌灵注射液，此药液经静脉滴注，主要治疗急性白血病、肝癌、淋巴瘤，对急粒临床验证效果最佳，毒副作用很小。
本发明癌灵注射液主要由三氧化二砷、氯化钠和注射用水，经煮沸、过滤制成注射液，其特征在于：由三氧化二砷、氯化钠、注射用水，经煮沸过滤灭菌制成癌灵注射液，其中三氧化二砷1—10克，氯化钠8克，注射用水1000毫升。将注射用水1000毫升煮沸，加入三氧化二砷煮沸半小时，完全溶解后，加入氯化钠，再补加注射用水至1000毫升，用G3垂熔玻璃漏斗过滤、灌注、熔封、灭菌即可。
癌灵注射液的药理：
经实验证明，该药对白血病细胞膜的破坏、DNA、RNA合成抑制及克隆增殖能力的丧失是有较强的作用；体内、体外实验证实有显著的杀伤白血病细胞作用；并有诱导白血病细胞向正常细胞分化作用；可促进骨髓造血功能的恢复；可通过血脑屏障；电镜观察，超微结构病理细胞确向正常细胞转化。
使用时，成人每日10毫升癌灵注射液，加入10％葡萄糖500毫升，用静脉滴注，四周为一疗程。儿童按年龄递减。使用时可根据癌灵注射液的浓度不同决定用量。
本发明与现有的技术相比：此注射液对急性早幼粒细胞性白血病，治疗缓解率高，长期存活率大。完全缓解率为84％，长期存活者已达21年之久。实验证明该药对白血病细胞膜的破坏、抑制DNA、RNA合成及克隆增殖能力的丧失具有较强的作用；对白血病细胞有显著的杀伤作用；并有诱导白血病细胞向正常细胞分化作用；可促进骨髓造血功能的恢复。此药可通过血脑屏障，这是多种化疗药品所不及的，因此很少合并脑膜白血病。对巨核细胞有促进增生作用，可使血小板迅速恢复，因而很少发生凝血机制障碍而出血。同时此药对骨髓造血功能无抑制作用，可很快改善贫血状态。该注射液已获国家部级科技进步二等奖。
本发明的实施例：
癌灵注射液主要由三氧化二砷、氯化钠和注射用水组成，其中三氧化二砷1—10克，氯化钠8克，注射用水煮沸、过滤、灭菌而成。
取三氧化二砷10克、氯化钠8克、注射用水1000毫升。先将1000毫升注射用水加热煮沸，加入三氧化二砷10克继续煮沸30分钟，当完全溶解后加入8克氯化钠，同时补加入注射用水至1000毫升，用G3垂熔玻璃漏斗过滤后，灌注、熔解、灭菌即制成癌灵注射液。
本发明的临床病例：
临床统计110名急性早幼粒细胞性白血病患者，男性69例，女性41例，年龄在13—65岁。入院时有不同程度的出血91例(82.7％)，不同部位感染95例(86.4％)。血象化验红蛋白≤100g/L者101例(91.8％)；白细胞≥10×109/L者82例(25.5％)；血小板≤100×109/L106例(96.3％)。骨髓增生活跃者105例(95.4％)，早幼粒细胞≥60％者90例(81.8％)；经治2—4周治疗后，在幼稚细胞减少的同时白细胞总数随之由质变到量变，相继血小板上升，血红蛋白上升，同时可见幼红细胞。骨髓可见异常原早粒细胞质变化的同时总数下降，红系增生转活跃，成熟巨核细胞增多，临床症状明显好转。
其结果完全缓解为80％，部分缓解为3.6％，死亡16.4％，总缓解率为84％，死亡病例均以出血及严重感染为主。
20年来对24例完全缓解的病例进行了长期随访，其中5例均在完全缓解后1—4年内死于严重感染及脑出血。另外19例均存活10年以上，其中有17例目前仍健在，最长者已存活21年。

Claims (1)

1、一种癌灵注射液，其特征在于：由三氧化二砷、氯化钠、注射用水，经煮沸过滤灭菌制成癌灵注射液，其中三氧化二砷1—10克，氯化钠8克，注射用水1000毫升。
CN95108768A 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液 Expired - Lifetime CN1044559C (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN95108768A CN1044559C (zh) 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液
US08/702,011 US6720011B1 (en) 1995-08-23 1996-08-23 Injectable composition for cancer treatment
US10/715,166 US20040101573A1 (en) 1995-08-23 2003-11-17 Injectable composition for cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN95108768A CN1044559C (zh) 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液

Publications (2)

Publication Number Publication Date
CN1121807A true CN1121807A (zh) 1996-05-08
CN1044559C CN1044559C (zh) 1999-08-11

Family

ID=5076886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95108768A Expired - Lifetime CN1044559C (zh) 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液

Country Status (2)

Country Link
US (2) US6720011B1 (zh)
CN (1) CN1044559C (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055344A1 (en) * 1998-04-24 1999-11-04 Daopei Lu Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
EP0955052A1 (en) * 1998-05-08 1999-11-10 Ill-Ju Bae Arsenic hexaoxide (As4O6) for use in cancer therapy and its pharmaceutical composition
US6723351B2 (en) 1997-11-10 2004-04-20 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6875451B2 (en) 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN103393719A (zh) * 2013-08-07 2013-11-20 刘怀振 一种三氧化二砷口服液的生产方法
CN107982278A (zh) * 2017-12-15 2018-05-04 哈尔滨医科大学 一种用于治疗血管生成介导疾病的药物及应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559208A1 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
CN104768875A (zh) 2012-09-20 2015-07-08 于伽·纳拉扬·本德勒 纳米三氧化二砷的生物合成方法及其在治疗包括癌症的疾病中的用途
EP3250214B1 (en) * 2015-02-01 2021-09-01 Syros Pharmaceuticals, Inc. High surface-area lyophilized compositions comprising arsenic for oral administration in patients
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US9700580B1 (en) 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO930510A1 (it) * 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
EP1964557B1 (en) * 1997-11-10 2013-01-02 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US7205001B2 (en) 1997-10-15 2007-04-17 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US7179493B2 (en) 1997-10-15 2007-02-20 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US7163703B2 (en) 1997-10-15 2007-01-16 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US7132116B2 (en) 1997-10-15 2006-11-07 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US6770304B2 (en) 1997-11-10 2004-08-03 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6723351B2 (en) 1997-11-10 2004-04-20 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6861076B2 (en) 1997-11-10 2005-03-01 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US8273379B2 (en) 1997-11-10 2012-09-25 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6884439B2 (en) 1997-11-10 2005-04-26 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6982096B2 (en) 1997-11-10 2006-01-03 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US7879364B2 (en) 1997-11-10 2011-02-01 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6855339B2 (en) 1997-11-10 2005-02-15 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US7138147B2 (en) 1998-04-24 2006-11-21 Daopei Lu Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
AU748795B2 (en) * 1998-04-24 2002-06-13 Daopei Lu Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
US6733792B1 (en) 1998-04-24 2004-05-11 Daopei Lu Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
WO1999055344A1 (en) * 1998-04-24 1999-11-04 Daopei Lu Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
EP0955052A1 (en) * 1998-05-08 1999-11-10 Ill-Ju Bae Arsenic hexaoxide (As4O6) for use in cancer therapy and its pharmaceutical composition
CN103393719A (zh) * 2013-08-07 2013-11-20 刘怀振 一种三氧化二砷口服液的生产方法
CN103393719B (zh) * 2013-08-07 2014-07-23 骆红宇 一种三氧化二砷口服液的生产方法
CN107982278A (zh) * 2017-12-15 2018-05-04 哈尔滨医科大学 一种用于治疗血管生成介导疾病的药物及应用

Also Published As

Publication number Publication date
US20040101573A1 (en) 2004-05-27
CN1044559C (zh) 1999-08-11
US6720011B1 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
CN1121807A (zh) 癌灵注射液
Whalley et al. Oxytocin and water intoxication
AP1185A (en) Novel pharmaceutical composition for the use in emergency treatment and preparation method thereof.
CN1057445C (zh) 一种抗癌生物活性肽制剂的制备方法
CN109091530B (zh) 紫苏叶提取物在预防或治疗再生障碍性贫血中的应用
CN109793885A (zh) 一种用于预防或缓解贫血的复合多肽的制备方法
CN101703497B (zh) 绿原酸在制备对脾脏造血干细胞损伤有保护、修复作用的药物中的用途
Ter Borg et al. Use of sodium hydroxide solution to clear partially occluded vascular access ports
CN101212963B (zh) 绿原酸在制备具有增加骨髓细胞功效的药物中的用途
CN1087610C (zh) 香菇多糖注射液及其制备方法
CN1190205C (zh) 苦碟子注射液及其制备方法
CN102240261A (zh) 一种葡甘露聚糖注射液的制备方法及其医学用途
CN101019950B (zh) 一种清开灵大输液制剂及其制备方法
CN113332327A (zh) 西洋参黄芪制剂在制备提高免疫力的产品中的应用
CN111529549A (zh) 一种抗菌抗病毒的高化合价电解银离子溶液及其制备方法
CN100998585A (zh) 一种盐酸甲氯芬酯注射液的制剂及其制备方法
CN1120002C (zh) 硝酸铵在制药、食品和保健品中的应用
CN101695485A (zh) 绿原酸在制备治疗血小板减少症、贫血的药物中的用途
CN101019949B (zh) 清开灵大输液制剂及其制备方法
CN200951242Y (zh) 一次性使用无菌过滤型静脉推注注射器
EP0778026A1 (en) Remedy for endotoxinemia and multiple organ failure induced thereby
KR20020031404A (ko) 혈장 대체 조성물
CN1468600A (zh) 多索茶碱葡萄糖注射液的制备方法
CN1240430C (zh) 预防和治疗慢性疲劳综合症的药物
CN1283272C (zh) 一种抗癌药物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: HARBIN FIRST HOSPITAL

Document name: Invalidation case notification

CX01 Expiry of patent term

Expiration termination date: 20150823

Granted publication date: 19990811

EXPY Termination of patent right or utility model